Contineum Therapeutics (CTNM) Competitors

$13.71 +0.06 (+0.44%)

As of 03:03 PM Eastern

CTNM vs. OCUL, BHC, AUPH, STOK, and ANAB

Should you buy Contineum Therapeutics stock or one of its competitors? MarketBeat compares Contineum Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Contineum Therapeutics include Ocular Therapeutix (OCUL), Bausch Health Cos (BHC), Aurinia Pharmaceuticals (AUPH), Stoke Therapeutics (STOK), and AnaptysBio (ANAB). These companies are all part of the "pharmaceutical products" industry.

How does Contineum Therapeutics compare to Ocular Therapeutix?

Ocular Therapeutix (NASDAQ:OCUL) and Contineum Therapeutics (NASDAQ:CTNM) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, media sentiment, risk, analyst recommendations, valuation and institutional ownership.

Contineum Therapeutics has a net margin of 0.00% compared to Ocular Therapeutix's net margin of -558.24%. Contineum Therapeutics' return on equity of -27.09% beat Ocular Therapeutix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocular Therapeutix	-558.24%	-64.28%	-48.15%
Contineum Therapeutics	N/A	-27.09%	-25.64%

In the previous week, Ocular Therapeutix had 13 more articles in the media than Contineum Therapeutics. MarketBeat recorded 23 mentions for Ocular Therapeutix and 10 mentions for Contineum Therapeutics. Contineum Therapeutics' average media sentiment score of 0.77 beat Ocular Therapeutix's score of -0.03 indicating that Contineum Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocular Therapeutix	2 Very Positive mention(s)	5 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Contineum Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ocular Therapeutix currently has a consensus target price of $23.78, suggesting a potential upside of 160.01%. Contineum Therapeutics has a consensus target price of $19.50, suggesting a potential upside of 42.28%. Given Ocular Therapeutix's stronger consensus rating and higher probable upside, analysts clearly believe Ocular Therapeutix is more favorable than Contineum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocular Therapeutix	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
Contineum Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Contineum Therapeutics has lower revenue, but higher earnings than Ocular Therapeutix. Contineum Therapeutics is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocular Therapeutix	$51.95M	38.54	-$265.94M	-$1.46	N/A
Contineum Therapeutics	$50M	10.25	-$59.98M	-$1.95	N/A

Ocular Therapeutix has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market. Comparatively, Contineum Therapeutics has a beta of 0.89, indicating that its share price is 11% less volatile than the broader market.

59.2% of Ocular Therapeutix shares are held by institutional investors. 2.3% of Ocular Therapeutix shares are held by company insiders. Comparatively, 11.3% of Contineum Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Ocular Therapeutix beats Contineum Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Contineum Therapeutics compare to Bausch Health Cos?

Bausch Health Cos (NYSE:BHC) and Contineum Therapeutics (NASDAQ:CTNM) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and media sentiment.

78.7% of Bausch Health Cos shares are held by institutional investors. 20.7% of Bausch Health Cos shares are held by company insiders. Comparatively, 11.3% of Contineum Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Bausch Health Cos presently has a consensus target price of $8.00, suggesting a potential upside of 48.01%. Contineum Therapeutics has a consensus target price of $19.50, suggesting a potential upside of 42.28%. Given Bausch Health Cos' higher probable upside, equities research analysts clearly believe Bausch Health Cos is more favorable than Contineum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch Health Cos	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Contineum Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Bausch Health Cos has higher revenue and earnings than Contineum Therapeutics. Contineum Therapeutics is trading at a lower price-to-earnings ratio than Bausch Health Cos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch Health Cos	$10.27B	0.20	$157M	-$3.24	N/A
Contineum Therapeutics	$50M	10.25	-$59.98M	-$1.95	N/A

Bausch Health Cos has a beta of 0.42, meaning that its share price is 58% less volatile than the broader market. Comparatively, Contineum Therapeutics has a beta of 0.89, meaning that its share price is 11% less volatile than the broader market.

Contineum Therapeutics has a net margin of 0.00% compared to Bausch Health Cos' net margin of -11.47%. Contineum Therapeutics' return on equity of -27.09% beat Bausch Health Cos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch Health Cos	-11.47%	-2,922.77%	5.63%
Contineum Therapeutics	N/A	-27.09%	-25.64%

In the previous week, Contineum Therapeutics had 9 more articles in the media than Bausch Health Cos. MarketBeat recorded 10 mentions for Contineum Therapeutics and 1 mentions for Bausch Health Cos. Contineum Therapeutics' average media sentiment score of 0.77 beat Bausch Health Cos' score of 0.50 indicating that Contineum Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bausch Health Cos	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Contineum Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Contineum Therapeutics beats Bausch Health Cos on 9 of the 16 factors compared between the two stocks.

How does Contineum Therapeutics compare to Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals (NASDAQ:AUPH) and Contineum Therapeutics (NASDAQ:CTNM) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, dividends and valuation.

Aurinia Pharmaceuticals has a beta of 1.44, suggesting that its stock price is 44% more volatile than the broader market. Comparatively, Contineum Therapeutics has a beta of 0.89, suggesting that its stock price is 11% less volatile than the broader market.

Aurinia Pharmaceuticals currently has a consensus price target of $17.25, indicating a potential upside of 7.97%. Contineum Therapeutics has a consensus price target of $19.50, indicating a potential upside of 42.28%. Given Contineum Therapeutics' higher probable upside, analysts clearly believe Contineum Therapeutics is more favorable than Aurinia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurinia Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Contineum Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Aurinia Pharmaceuticals has higher revenue and earnings than Contineum Therapeutics. Contineum Therapeutics is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurinia Pharmaceuticals	$283.05M	7.26	$287.20M	$2.17	7.36
Contineum Therapeutics	$50M	10.25	-$59.98M	-$1.95	N/A

36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. 12.2% of Aurinia Pharmaceuticals shares are held by company insiders. Comparatively, 11.3% of Contineum Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Aurinia Pharmaceuticals and Aurinia Pharmaceuticals both had 10 articles in the media. Aurinia Pharmaceuticals' average media sentiment score of 0.84 beat Contineum Therapeutics' score of 0.77 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aurinia Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Contineum Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aurinia Pharmaceuticals has a net margin of 99.97% compared to Contineum Therapeutics' net margin of 0.00%. Aurinia Pharmaceuticals' return on equity of 26.62% beat Contineum Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurinia Pharmaceuticals	99.97%	26.62%	19.65%
Contineum Therapeutics	N/A	-27.09%	-25.64%

Summary

Aurinia Pharmaceuticals beats Contineum Therapeutics on 11 of the 14 factors compared between the two stocks.

How does Contineum Therapeutics compare to Stoke Therapeutics?

Contineum Therapeutics (NASDAQ:CTNM) and Stoke Therapeutics (NASDAQ:STOK) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, media sentiment, earnings and analyst recommendations.

Contineum Therapeutics has a beta of 0.89, suggesting that its stock price is 11% less volatile than the broader market. Comparatively, Stoke Therapeutics has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market.

In the previous week, Stoke Therapeutics had 5 more articles in the media than Contineum Therapeutics. MarketBeat recorded 15 mentions for Stoke Therapeutics and 10 mentions for Contineum Therapeutics. Contineum Therapeutics' average media sentiment score of 0.77 beat Stoke Therapeutics' score of 0.42 indicating that Contineum Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Contineum Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Stoke Therapeutics	1 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Contineum Therapeutics currently has a consensus target price of $19.50, indicating a potential upside of 42.28%. Stoke Therapeutics has a consensus target price of $41.83, indicating a potential upside of 30.08%. Given Contineum Therapeutics' higher possible upside, research analysts plainly believe Contineum Therapeutics is more favorable than Stoke Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Contineum Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Stoke Therapeutics	0 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.92

Stoke Therapeutics has higher revenue and earnings than Contineum Therapeutics. Stoke Therapeutics is trading at a lower price-to-earnings ratio than Contineum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Contineum Therapeutics	$50M	10.25	-$59.98M	-$1.95	N/A
Stoke Therapeutics	$184.42M	10.86	-$6.89M	-$2.81	N/A

Contineum Therapeutics has a net margin of 0.00% compared to Stoke Therapeutics' net margin of -529.20%. Contineum Therapeutics' return on equity of -27.09% beat Stoke Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Contineum Therapeutics	N/A	-27.09%	-25.64%
Stoke Therapeutics	-529.20%	-51.16%	-43.78%

Summary

Stoke Therapeutics beats Contineum Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Contineum Therapeutics compare to AnaptysBio?

Contineum Therapeutics (NASDAQ:CTNM) and AnaptysBio (NASDAQ:ANAB) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability.

Contineum Therapeutics has a net margin of 0.00% compared to AnaptysBio's net margin of -5.64%. Contineum Therapeutics' return on equity of -27.09% beat AnaptysBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Contineum Therapeutics	N/A	-27.09%	-25.64%
AnaptysBio	-5.64%	-1,101.24%	-3.59%

AnaptysBio has higher revenue and earnings than Contineum Therapeutics. AnaptysBio is trading at a lower price-to-earnings ratio than Contineum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Contineum Therapeutics	$50M	10.25	-$59.98M	-$1.95	N/A
AnaptysBio	$234.60M	8.15	-$13.23M	-$0.52	N/A

In the previous week, Contineum Therapeutics and Contineum Therapeutics both had 10 articles in the media. Contineum Therapeutics' average media sentiment score of 0.77 beat AnaptysBio's score of 0.50 indicating that Contineum Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Contineum Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AnaptysBio	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Contineum Therapeutics has a beta of 0.89, meaning that its share price is 11% less volatile than the broader market. Comparatively, AnaptysBio has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market.

Contineum Therapeutics presently has a consensus target price of $19.50, suggesting a potential upside of 42.28%. AnaptysBio has a consensus target price of $76.18, suggesting a potential upside of 15.91%. Given Contineum Therapeutics' higher probable upside, equities analysts clearly believe Contineum Therapeutics is more favorable than AnaptysBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Contineum Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
AnaptysBio	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

Summary

Contineum Therapeutics and AnaptysBio tied by winning 7 of the 14 factors compared between the two stocks.

Get Contineum Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CTNM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CTNM vs. The Competition

Export

Metric	Contineum Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$512.13M	$3.41B	$6.27B	$12.13B
Dividend Yield	N/A	2.25%	2.78%	5.23%
P/E Ratio	-7.02	15.30	20.53	25.45
Price / Sales	10.25	302.57	545.62	75.37
Price / Cash	N/A	56.93	27.81	36.29
Price / Book	1.96	6.81	9.60	6.64
Net Income	-$59.98M	$24.11M	$3.55B	$333.40M
7 Day Performance	-4.76%	-1.67%	-0.34%	-0.45%
1 Month Performance	6.49%	3.64%	6.09%	7.83%
1 Year Performance	257.83%	70.97%	38.53%	35.63%

Contineum Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CTNM Contineum Therapeutics	3.0377 of 5 stars	$13.71 +0.4%	$19.50 +42.3%	+252.7%	$512.13M	$50M	N/A	31	News Coverage Earnings Report Upcoming Earnings Analyst Upgrade Short Interest Decrease
OCUL Ocular Therapeutix	3.2092 of 5 stars	$9.85 +1.4%	$23.78 +141.5%	+30.5%	$2.16B	$51.95M	N/A	230
BHC Bausch Health Cos	2.3063 of 5 stars	$5.64 -0.1%	$8.00 +42.0%	+17.7%	$2.11B	$10.27B	N/A	20,300
AUPH Aurinia Pharmaceuticals	2.6415 of 5 stars	$16.10 +0.4%	$17.25 +7.1%	+96.5%	$2.09B	$283.05M	7.75	300	Earnings Report
STOK Stoke Therapeutics	2.5204 of 5 stars	$33.15 +0.6%	$41.83 +26.2%	+252.9%	$2.07B	$184.42M	N/A	100	News Coverage Earnings Report Analyst Forecast Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CTNM) was last updated on 5/12/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Contineum Therapeutics (CTNM) Competitors

CTNM vs. OCUL, BHC, AUPH, STOK, and ANAB

How does Contineum Therapeutics compare to Ocular Therapeutix?

Summary

How does Contineum Therapeutics compare to Bausch Health Cos?

Summary

How does Contineum Therapeutics compare to Aurinia Pharmaceuticals?

Summary

How does Contineum Therapeutics compare to Stoke Therapeutics?

Summary

How does Contineum Therapeutics compare to AnaptysBio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTNM vs. The Competition

Contineum Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Contineum Therapeutics (CTNM) Competitors

CTNM vs. OCUL, BHC, AUPH, STOK, and ANAB

How does Contineum Therapeutics compare to Ocular Therapeutix?

Is OCUL or CTNM more profitable?

Does the media refer more to OCUL or CTNM?

Do analysts rate OCUL or CTNM?

Which has preferable earnings & valuation, OCUL or CTNM?

Which has more volatility & risk, OCUL or CTNM?

Do insiders & institutionals have more ownership in OCUL or CTNM?

Summary

How does Contineum Therapeutics compare to Bausch Health Cos?

Do institutionals and insiders hold more shares of BHC or CTNM?

Do analysts recommend BHC or CTNM?

Which has preferable earnings & valuation, BHC or CTNM?

Which has more risk & volatility, BHC or CTNM?

Is BHC or CTNM more profitable?

Does the media refer more to BHC or CTNM?

Summary

How does Contineum Therapeutics compare to Aurinia Pharmaceuticals?

Which has more risk & volatility, AUPH or CTNM?

Do analysts recommend AUPH or CTNM?

Which has stronger earnings & valuation, AUPH or CTNM?

Do insiders and institutionals believe in AUPH or CTNM?

Does the media favor AUPH or CTNM?

Is AUPH or CTNM more profitable?

Summary

How does Contineum Therapeutics compare to Stoke Therapeutics?

Which has more volatility and risk, CTNM or STOK?

Does the media refer more to CTNM or STOK?

Do analysts rate CTNM or STOK?

Which has higher earnings & valuation, CTNM or STOK?

Is CTNM or STOK more profitable?

Summary

How does Contineum Therapeutics compare to AnaptysBio?

Is CTNM or ANAB more profitable?

Which has stronger earnings & valuation, CTNM or ANAB?

Does the media prefer CTNM or ANAB?

Which has more volatility & risk, CTNM or ANAB?

Do analysts recommend CTNM or ANAB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTNM vs. The Competition

Contineum Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools